Products
Physicians - Indication   

Suprax® is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms1

  Indication

Suprax® Tablets Suprax® Oral Suspension

Otitis media*

-

Pharyngitis/tonsillitis

Acute bronchitis & acute exacerbations of chronic bronchitis

Uncomplicated urinary tract infections§

Uncomplicated gonorrhea||


* Otitis media caused by Haemophilus influenzae (ß-lactamase positive and negative strains, Moraxella (Branhamella) catarrhalis (most of which are ß-lactamase positive) and S. pyogenes. Otitis media should be treated with suspension only.
   
Pharyngitis and tonsillitis caused by S. pyogenes. Suprax® is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of Suprax® in the subsequent prevention of rheumatic fever are not available. Penicillin is the only drug with proven efficacy in the prophylaxis of rheumatic fever.
 
 
 
   
Acute bronchitis and acute exacerbations of chronic bronchitis caused by Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase positive and negative strains).
 
   
§ Uncomplicated urinary tract infections caused by E. coli and Proteus mirabilis.
   
|| Uncomplicated gonorrhea (cervical/urethral) caused by Neisseria gonorrhoeae (penicillinase- and non–penicillinase-producing strains).
 
Proven efficacy
In otitis media:
Bacteriologic outcome of otitis media at 2 to 4 weeks post-therapy: 81% efficacy in pediatric patients with otitis media in US NDA trials with Suprax® 8 mg/kg QD (N=387)1
In a recent clinical study in otitis media (N=313), Suprax® at 8 mg/kg QD provided efficacy comparable to that of amoxicillin/clavulanic acid at 40 mg/kg TID2

In uncomplicated urinary tract infections:

In a study of adults with complicated or uncomplicated UTI (n=60), 99% of patients were cured or improved after treatment with Suprax® 400 mg tablets for 3 to 7 days1
In a study of children aged 6 months to 13 years (n=38) treated with Suprax®, clinical success was noted in 100% of patients after the first 72 hours of treatment2

In uncomplicated gonorrhea:

The only oral antibiotic recommended by the CDC
For the treatment of uncomplicated urogenital and anorectal gonorrhea, the CDC recommends ceftriaxone 125 mg (single intramuscular injection) or Suprax® 400 mg (single oral dose)3
References: 1. Ludwig E. Cefixime in the treatment of respiratory or urinary tract infections. Chemotherapy. 1998;44(suppl 1):31-34. 2. Dagan R, Einhorn M, Lang R, et al. Once daily cefixime compared with twice daily trimethoprim/sulfamethoxazole for treatment of urinary tract infections in infants and children. Pediatr Infect Dis J. 1992;11:198-203. 3. Centers for Disease Control and Prevention. Update to CDC’s Sexually Transmitted Disease Treatment Guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR. 2007;56:332-336.
 
Please view Package insert for more information about side effects and safe use of Suprax®
 
Copyright © 2010, Lupin Pharmaceuticals, Inc., All Rights Reserved.
Created and Designed by Gayatri Microsystems